It can be hypothesized that the benefit from adjuvant gemcitabine in pancreatic cancer patients carrying TP53 mutations could be related, at least in part, to a concomitant increased expression and membrane localization of hENT-1 in tumor tissue, similarly to what we observed in iCCA patients. This evidence concerns the gene TP53 and neoplasm.